Ipamorelin: Research Chemistry and Literature

Origin and identification

GHSR-1a reached the literature before its most selective synthetic ligand did. Howard and colleagues cloned the human and porcine growth hormone secretagogue receptor from pituitary and hypothalamic tissue in 1996, establishing it as a seven transmembrane G protein coupled receptor distinct from the growth hormone releasing hormone receptor, and showing that a structurally diverse family of synthetic secretagogues, developed over the previous decade without a confirmed target, converged on this one binding site.

Raun and colleagues reported ipamorelin two years later as the product of a truncation series built on GHRP-1. Removing the central Ala-Trp dipeptide and adjusting the flanking residues produced a pentapeptide that released growth hormone from primary rat pituitary cells with potency and efficacy comparable to GHRP-6, the reference compound of that era. A related series published by Ankersen and colleagues in 1998 extended the ipamorelin scaffold with backbone N-methylations and a benzoic acid derived spacer, reporting further gains in potency in the same rat pituitary cell assay and in anaesthetised rats.

Preclinical research context

Selectivity, not potency, is what distinguishes ipamorelin from the secretagogues that preceded it. Earlier growth hormone releasing peptides such as GHRP-6 reliably co-release adrenocorticotropic hormone, cortisol and prolactin alongside growth hormone, an effect attributed to overlapping activity at corticotroph and lactotroph cell populations. Raun and colleagues tested ipamorelin across the same panel in rats and pigs and found no meaningful elevation of adrenocorticotropic hormone, cortisol, prolactin or thyroid stimulating hormone at concentrations far above what was needed for growth hormone release, a margin the original paper put at roughly two hundred fold. Pharmacological blockade experiments using growth hormone releasing hormone receptor and secretagogue receptor antagonists in the same study assigned the growth hormone response specifically to the secretagogue receptor pathway rather than to any cross-talk with the growth hormone releasing hormone receptor.

That selectivity places ipamorelin in a different pharmacological category from the growth hormone releasing hormone analogues it is often studied alongside, including CJC-1295, covered in a separate entry. The two act at distinct receptors, GHSR-1a and GHRHR respectively, and reported pharmacology across the secretagogue literature describes their effects on growth hormone release as at least additive when the two receptor systems are engaged together. A short elimination half-life on the order of two hours has been reported for the unconjugated pentapeptide, consistent with rapid proteolytic clearance typical of a secretagogue peptide that carries no half-life extension chemistry of its own.

Analytical characterisation

Purity is measured by reverse phase HPLC. A C18 column with a water and acetonitrile gradient modified with trifluoroacetic acid resolves the main peak from truncated and epimerised impurities, and the histidine, D-2-naphthylalanine and D-phenylalanine residues give the molecule strong ultraviolet absorbance, so 210 and 280 nanometre detection are both informative, the latter tracking the aromatic side chains specifically.

Identity rests on mass spectrometry. Electrospray ionisation in positive mode gives a singly or doubly protonated ion consistent with the 711.9 dalton average mass, and tandem fragmentation reads out the sequence directly, which matters here because a D to L epimerisation at the 2-naphthylalanine or phenylalanine position would not change the mass at all. Certificates of Analysis for material listed here are issued by Janoshik Analytical and report identity and chromatographic purity for the specific lot shipped.

Handling and storage

The lyophilised powder tolerates ambient conditions in transit. Peptides of this size ship without a cold chain as a matter of routine, and brief warmth during carriage does not compromise a dry, sealed vial. Check the seal and the desiccant on arrival.

Store the sealed vial at minus 20 degrees Celsius, in the dark, on receipt. The histidine imidazole side chain and the two aromatic side chains are not especially photolabile on their own, but a cool, dark, dry environment remains the safer default for any peptide held longer than a few weeks.

Reconstituted material should be held at 2 to 8 degrees Celsius and used within a short window. Divide the solution into single-use aliquots before the first freeze rather than cycling a stock vial through repeated freeze-thaw, and label each aliquot with the date it was prepared and the diluent used.

References

1. A receptor in pituitary and hypothalamus that functions in growth hormone release
2. Ipamorelin, the first selective growth hormone secretagogue
3. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin
4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
5. Ipamorelin, PubChem Compound Summary CID 9831659

Related compounds